

ACS-GHS May Seminar Michael Liebman



Wednesday, May 24th
7:00 - 8:00 pm CDT
via Zoom

Register to receive the meeting link at <https://acsghs.wildapricot.org/event-5260472>

Decision Making in Drug Development and Medicine: The Good, the Bad, the Ugly

Critical analysis of the decision-making processes and the application of systems thinking and critical thinking are needed to understand the full impact of factors beyond "the chemistry" and build models to represent and analyze the full complexity. Such factors can range from real world data to public health to political and economic constraints. This seminar will also discuss how to move beyond the hype to the real world.

Biography: Michael N. Liebman, Ph.D. is the Managing Director of IPQ Analytics, LLC and Strategic Medicine, Inc after serving as the Executive Director of the Windber Research Institute (now Chan Soon-Shiong Institute for Molecular Medicine) from 2003-2007. He is an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery, First Hospital of Wenzhou Medical University and also Fudan University. He serves on the Advisory Board for the International Park for Translational Biomedicine (Shanghai) and the Center of Biomedical and Health Research in Data Sciences, Univ Massachusetts (Lowell). His research focuses on computational models of disease progression that stress risk detection, disease processes and clinical pathway modeling, and disease stratification from the clinical perspective. He utilizes systems-based approaches and design thinking to represent and analyze risk/benefit analysis in pharmaceutical development and healthcare and reimbursement. Current application areas include: multiple sclerosis, heart failure, triple negative breast cancer, COVID and prematurity/infant-maternal morbidity and mortality.